INOVIO PHARMACEUTICALS, INC. Form 8-K March 23, 2012

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report

(Date of earliest event reported)

March 19, 2012

INOVIO PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Edgar Filing: INOVIO PHARMACEUTICALS, INC. - Form 8-K

	Delaware (State or other jurisdiction	001-14888 (Commission	33-0969592 (I.R.S. Employer
	of incorporation)	File Number)	Identification No.)
1787 Sentry Parkway West			
Building 18, Suite 400			
	Blue Bell, Pennsylvania (Address of principal executive offices Registrant s telephone num) nber, including area code <u>: (267) 440-420</u> 0	19422 (Zip Code)
N/A			
(Former name or former address, if changed since last report)			
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:			
	Written communications pursuant to Rule 425 under the Sec	urities Act (17 CFR 230.425)	
	Soliciting material pursuant to Rule 14a-12 under the Exchar	nge Act (17 CFR 240.14a-12)	
	Pre-commencement communications pursuant to Rule 14d-2	(b) under the Exchange Act (17 CFR 240.14d	-2(b))
	Pre-commencement communications pursuant to Rule 13e-4	(c) under the Exchange Act (17 CFR 240.13e-	4(c))

Edgar Filing: INOVIO PHARMACEUTICALS, INC. - Form 8-K

<u>Item 5.02.</u> <u>Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</u>

On March 19, 2012, Keith H. Wells, Ph.D., notified us that he will not stand for re-election to our board of directors at our 2012 annual meeting of stockholders.

Edgar Filing: INOVIO PHARMACEUTICALS, INC. - Form 8-K

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

INOVIO PHARMACEUTICALS, INC.

By: /s/ Peter Kies Peter Kies, Chief Financial Officer

Date: March 23, 2012